There is evidence from a previous meta-analysis that GLP-1RA confer a similar reduction in MACE in both sexes, whereas SGLT-2 inhibitors reduce the risk of MACE more in men than in women [31]
Manufacturers are focusing on: Designing smaller, nutrient-dense meal formats Enhancing protein and fiber composition Improving digestive tolerance and satiety performance Expanding direct-to-consumer and pharmacy-adjacent distribution This shift reflects a move from general weight-management foods to targeted nutritional solutions aligned with GLP-1 usage patterns
For example, previous research has shown that females appear to be more sensitive to the ability of GLP-1R agonists to suppress food intake and body weight (e.g., Richard et al., 2016)
[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Gonzlez-Muniesa P, Mrtinez-Gonzlez M-A, Hu FB, Desprs J-P, Matsuzawa Y, Loos RJF, et al